Held on 21 June 2017
Medicamen Biotech announced that the Board of Directors at its meeting held on 21 June 2017 has approved the following -Approval to the Issue & Allot 306000 Warrants, convertible into Equity Shares of the Company at a price of Rs. 543/- per warrant (including a premium of Rs.533/- each), in accordance with the SEBI (ICDR) Regulations, 2009 on Preferential Allotment basis to a promoter group and non promoter group/ Investors.
Calling of an Extraordinary General Meeting, of the Company in relation to the Preferential Issue as aforesaid on 17 July, 2017.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app